What is Phosphorex?
Phosphorex operates as a specialized CDMO with over two decades of experience, focusing on the development and cGMP manufacturing of lipid and polymeric nanoparticles. Their expertise lies in creating targeted and sustained-release drug delivery systems, aiming to enhance therapeutic efficacy and patient safety. The company provides a comprehensive suite of services, from initial formulation feasibility studies to full-scale manufacturing, catering to pharmaceutical and biotech firms seeking to advance their drug candidates through sophisticated delivery mechanisms. Phosphorex's commitment to collaborative development and reliable execution positions them as a key partner in bringing novel therapies to market.
How much funding has Phosphorex raised?
Phosphorex has raised a total of $470K across 2 funding rounds:
Debt
$150K
Debt
$320K
Debt (2020): $150K with participation from PPP
Debt (2021): $320K led by PPP
Key Investors in Phosphorex
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Phosphorex?
With its recent large-scale, late-stage funding, Phosphorex is poised for accelerated growth and expanded operational capacity. This strategic capital infusion is expected to fuel further innovation in particle-based drug delivery technologies and potentially broaden their service offerings. The company is likely to invest in enhancing its manufacturing capabilities to meet increasing demand and may explore strategic partnerships to extend its market reach. This financing round signals confidence in Phosphorex's business model and its potential to significantly impact the future of drug delivery.
See full Phosphorex company page
